226 related articles for article (PubMed ID: 37179366)
1. Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients.
Feng D; Wang J; Shi X; Li D; Wei W; Han P
Eur J Med Res; 2023 May; 28(1):172. PubMed ID: 37179366
[TBL] [Abstract][Full Text] [Related]
2. Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome.
Qian Y; Feng D; Wang J; Wei W; Wei Q; Han P; Yang L
Sci Rep; 2023 Jun; 13(1):9016. PubMed ID: 37270661
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
Front Immunol; 2022; 13():946209. PubMed ID: 36569837
[TBL] [Abstract][Full Text] [Related]
4. Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy.
Feng D; Wang J; Li D; Wu R; Wei W; Zhang C
Discov Oncol; 2023 Aug; 14(1):155. PubMed ID: 37624511
[TBL] [Abstract][Full Text] [Related]
5. Identification of senescence-related molecular subtypes and key genes for prostate cancer.
Feng DC; Zhu WZ; Shi X; Xiong Q; You J; Wei Q; Yang L
Asian J Androl; 2023; 25(2):223-229. PubMed ID: 36124532
[TBL] [Abstract][Full Text] [Related]
6. Establishment of novel ferroptosis-related prognostic subtypes correlating with immune dysfunction in prostate cancer patients.
Feng D; Tuo Z; Wang J; Ye L; Li D; Wu R; Wei W; Yang Y; Zhang C
Heliyon; 2024 Jan; 10(1):e23495. PubMed ID: 38187257
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
8. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer.
Feng D; Zhang F; Li D; Shi X; Xiong Q; Wei Q; Yang L
Immunology; 2022 Jun; 166(2):197-209. PubMed ID: 35271752
[TBL] [Abstract][Full Text] [Related]
9. Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy.
Feng D; Shi X; Zhang F; Xiong Q; Wei Q; Yang L
Front Immunol; 2022; 13():839362. PubMed ID: 35280985
[TBL] [Abstract][Full Text] [Related]
10. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
Yuen KC; Tran B; Anton A; Hamidi H; Costello AJ; Corcoran NM; Lawrentschuk N; Rainey N; Semira MCG; Gibbs P; Mariathasan S; Sandhu S; Kadel EE
Prostate; 2022 Jun; 82(9):993-1002. PubMed ID: 35435276
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer.
Lin BB; Lei HQ; Xiong HY; Fu X; Shi F; Yang XW; Yang YF; Liao GL; Feng YP; Jiang DG; Pang J
Comput Struct Biotechnol J; 2021; 19():4941-4953. PubMed ID: 34527198
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Stiff matrix induced srGAP2 tension gradients control migration direction in triple-negative breast cancer.
Li C; Zheng Z; Wu X; Xie Q; Liu P; Hu Y; Chen M; Liu L; Zhao W; Chen L; Guo J; Song Y
Theranostics; 2023; 13(1):59-76. PubMed ID: 36593959
[No Abstract] [Full Text] [Related]
17. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
Front Immunol; 2022; 13():777724. PubMed ID: 35154101
[TBL] [Abstract][Full Text] [Related]
18. Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer.
Acosta-Vega NL; Varela R; Mesa JA; Garai J; Baddoo MC; Gómez-Gutiérrez A; Serrano-Gómez SJ; Lemus MN; Serrano ML; Zabaleta J; Combita AL; Sanabria-Salas MC
Cancer Med; 2023 Feb; 12(4):4306-4320. PubMed ID: 36329628
[TBL] [Abstract][Full Text] [Related]
19. Aberrant
Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
